Entries by nacnkcell

ONK Therapeutics’ CSO Prof. M O’Dwyer and his Academic Group Present New Data Showing the Benefit of Knocking Out the Inhibitory Receptor CD96 on Human NK Cells in the Context of Multiple Myeloma at EHA 2021

The checkpoint inhibitor CD96 was shown conclusively to be an inhibitory receptor on human NK cells in the presence of multiple myeloma (MM) cells expressing CD155 CD96 knock out (KO) using CRISPR/Cas9 gene editing enhanced both NK cell cytotoxicity and cytokine release Efficient engineering of NK cells to genetically eliminate inhibitory receptor expression has the potential […]

ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies

Collaboration between ONK Therapeutics and Dr. David Finlay’s group at Trinity College Dublin, Ireland Two-year Enterprise Ireland Innovation Partnership Programme (IPP) project grant of €373,295 Research to explore metabolic reprogramming and engineering of natural killer (NK) cells for improved cancer therapy Galway, Ireland and San Diego, USA, 8 June  2021 – ONK Therapeutics Ltd, an […]

ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australia’s WEHI

Cytokine Inducible SH2 containing protein (CIS; encoded by the gene CISH) is a potent checkpoint in NK cell-mediated tumor immunity CISH knockout (KO) NK cells have been shown to be more efficient in eliminating cancer cells in in-vivo models Exclusive global license to WEHI patent for CISH KO in the field of NK cells builds […]

ONK Therapeutics Enters into a Research Agreement with NUI Galway to Support Optimization of its Dual-Targeted NK Cell Therapy against AML

Agreement with the National University of Ireland, Galway (NUI Galway), supervised by leading expert in the cellular environment in Acute Myeloid Leukaemia (AML), Dr. Eva Szegezdi Funded by ONK Therapeutics, the research will support engineering and optimization of its dual-targeted NK cell therapy candidate for AML (ONKT104) Aims to explore the potential added benefit of certain gene […]